Linagliptin/Metformin 1a Pharma

Linagliptin, the active ingredient in Linagliptin/Metformin 1a Pharma, is a DPP‑4 inhibitor presented as an oral tablet formulation for oral use. It is combined with metformin hydrochloride, a biguanide, to treat type 2 diabetes mellitus in adults when diet, exercise, and monotherapy are insufficient.

GNH USA supplies Linagliptin/Metformin 1a Pharma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation for export to multiple regions globally.

Linagliptin/Metformin is indicated for the management of type 2 diabetes mellitus, a chronic metabolic disorder characterized by hyperglycemia.

- Type 2 diabetes mellitus: improves overall glycemic control when added to diet and exercise. - Inadequate response to metformin alone: provides additional glucose‑lowering effect as part of combination therapy. - When combined with insulin or other antidiabetic agents: enhances insulin sensitivity and reduces post‑prandial glucose excursions.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Diarrhea: loose stools, often transient. - Headache: mild cranial discomfort. - Upper respiratory tract infection: cold‑like symptoms. - Vomiting: occasional emesis. - Abdominal pain: crampy discomfort.

Serious or Rare Side Effects: - Lactic acidosis: rare but life‑threatening metabolic disturbance. - Severe hypoglycemia: especially when combined with insulin secretagogues. - Pancreatitis: acute inflammation of the pancreas. - Hepatic failure: marked liver enzyme elevation. - Allergic reactions: rash, angioedema, or anaphylaxis. - Renal dysfunction: worsening kidney function in susceptible patients.

Patients should be evaluated for renal and hepatic function before initiating therapy and monitored periodically.

- Renal function monitoring: assess eGFR to ensure safe use. - Hepatic assessment: check liver enzymes for underlying disease. - Lactic acidosis risk: avoid in patients with severe heart failure or hypoxia. - Hypoglycemia vigilance: caution when used with sulfonylureas or insulin. - Cardiovascular status: monitor in patients with known cardiac disease. - Store at ambient temperature: keep in the original pack, protect from moisture and direct sunlight.

Linagliptin/Metformin may interact with several drug classes, requiring clinical awareness.

Major Interactions (Avoid): - Concomitant insulin secretagogues (e.g., sulfonylureas): risk of severe hypoglycemia. - Iodinated contrast agents: may precipitate lactic acidosis in susceptible patients. - Strong CYP3A4 inhibitors: can increase linagliptin exposure.

Moderate Interactions (Monitor Closely): - Diuretics: may affect renal clearance of metformin. - NSAIDs: can impair renal function, increasing metformin accumulation. - ACE inhibitors/ARBs: monitor renal function and potassium levels. - Beta‑blockers: may mask hypoglycemia symptoms. - Warfarin: potential alteration of INR, requiring monitoring.